Effects of the special extract ERr 731® from Rheum rhaponticum on estrogen-regulated targets in the uterotrophy model of ovariectomized rats

Journal of Steroid Biochemistry and Molecular Biology

Volumn 117, Issue 4-5, 2009, Pages 176-184

  Papke, Anja ^a   Kretzschmar, Georg ^a   Zierau, Oliver ^a   Kaszkin Bettag, Marietta ^b   Vollmer, Günter ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Health Research Services Ltd   (Germany)

Author keywords

Climacteric; Estrogen receptor; Gene expression; Phyto Strol ; Proliferation; Uterus

Indexed keywords

COMPLEMENT COMPONENT C3; CYCLINE; ERR 731; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; MESSENGER RNA; RHUBARB EXTRACT; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE EXPRESSION REGULATION; GROWTH STIMULATION; LOW DRUG DOSE; NONHUMAN; OVARIECTOMY; PROTEIN EXPRESSION; RAT; RHUBARB; UPREGULATION; UTERUS GROWTH; UTERUS WEIGHT;

ANIMALS; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; KI-67 ANTIGEN; ORGAN SIZE; OVARIECTOMY; PLANT EXTRACTS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RECEPTORS, ESTROGEN; RHEUM; RNA, MESSENGER; UTERINE DISEASES;

ANIMALIA; RATTUS; RHEUM RHAPONTICUM;

EID: 70350326282     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.09.011     Document Type: Article

References (53)

1. Nelson H.D. Menopause. Lancet 371 9614 (2008) 760-770
2. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-427
3. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
4. Heger M., Ventskovskiy B.M., Borzenko I., Kneis K.C., Rettenberger R., Kaszkin-Bettag M., and Heger P.W. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. Menopause 13 5 (2006) 744-759
5. Hasper I., Ventskovskiy B.M., Rettenberger R., Heger P.W., Riley D.S., and Kaszkin-Bettag M. Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms. Menopause 16 1 (2009) 117-131
6. Rupprich N., Hildebrand H., and Kindl H. Substrate specificity in vivo and in vitro in the formation of stilbenes. Biosynthesis of rhaponticin. Arch. Biochem. Biophys. 200 1 (1980) 72-78
7. Moller F., Zierau O., Jandausch A., Rettenberger R., Kaszkin-Bettag M., and Vollmer G. Subtype-specific activation of estrogen receptors by a special extract of Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds in U2OS human osteosarcoma cells. Phytomedicine 14 11 (2007) 716-726
8. Wober J., Moller F., Richter T., Unger C., Weigt C., Jandausch A., Zierau O., Rettenberger R., Kaszkin-Bettag M., and Vollmer G. Activation of estrogen receptor-beta by a special extract of Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds. J. Steroid Biochem. Mol. Biol. 107 3-5 (2007) 191-201
9. Diel P., Schmidt S., and Vollmer G. In vivo test systems for the quantitative and qualitative analysis of the biological activity of phytoestrogens. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 777 1-2 (2002) 191-202
10. Murphy L.J., and Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr. Rev. 11 3 (1990) 443-453
11. Ignar-Trowbridge D.M., Nelson K.G., Bidwell M.C., Curtis S.W., Washburn T.F., McLachlan J.A., and Korach K.S. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 89 10 (1992) 4658-4662
12. Murphy L.J., Murphy L.C., and Friesen H.G. Estrogen induces insulin-like growth factor-I expression in the rat uterus. Mol. Endocrinol. 1 7 (1987) 445-450
13. Norstedt G., Levinovitz A., and Eriksson H. Regulation of uterine insulin-like growth factor I mRNA and insulin-like growth factor II mRNA by estrogen in the rat. Acta Endocrinol. (Copenh.) 120 4 (1989) 466-472
14. Umayahara Y., Kawamori R., Watada H., Imano E., Iwama N., Morishima T., Yamasaki Y., Kajimoto Y., and Kamada T. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem. 269 23 (1994) 16433-16442
15. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., and Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133 4 (1984) 1710-1715
16. Kelman Z. PCNA: structure, functions and interactions. Oncogene 14 6 (1997) 629-640
17. Tsurimoto T. PCNA, a multifunctional ring on DNA. Biochim. Biophys. Acta 1443 1-2 (1998) 23-39
18. Gustafsson J.A. An update on estrogen receptors. Semin. Perinatol. 24 1 (2000) 66-69
19. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., Enmark E., Pettersson K., Warner M., and Gustafsson J.A. Mechanisms of estrogen action. Physiol. Rev. 81 4 (2001) 1535-1565
20. Lindberg M.K., Moverare S., Skrtic S., Gao H., Dahlman-Wright K., Gustafsson J.A., and Ohlsson C. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol. Endocrinol. 17 2 (2003) 203-208
21. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 9 (2001) e45
22. Kanno J., Onyon L., Peddada S., Ashby J., Jacob E., and Owens W. The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. Environ. Health Perspect. 111 12 (2003) 1550-1558
23. Kanno J., Onyon L., Peddada S., Ashby J., Jacob E., and Owens W. The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies. Environ. Health Perspect. 111 12 (2003) 1530-1549
24. Diel P., Geis R.B., Caldarelli A., Schmidt S., Leschowsky U.L., Voss A., and Vollmer G. The differential ability of the phytoestrogen genistein and of estradiol to induce uterine weight and proliferation in the rat is associated with a substance specific modulation of uterine gene expression. Mol. Cell Endocrinol. 221 1-2 (2004) 21-32
25. Diel P., Hertrampf T., Seibel J., Laudenbach-Leschowsky U., Kolba S., and Vollmer G. Combinatorial effects of the phytoestrogen genistein and of estradiol in uterus and liver of female Wistar rats. J. Steroid Biochem. Mol. Biol. 102 1-5 (2006) 60-70
26. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., and Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 10 (1998) 4252-4263
27. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., and Katzenellenbogen J.A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 44 24 (2001) 4230-4251
28. Harris H.A., Albert L.M., Leathurby Y., Malamas M.S., Mewshaw R.E., Miller C.P., Kharode Y.P., Marzolf J., Komm B.S., Winneker R.C., Frail D.E., Henderson R.A., Zhu Y., and Keith Jr. J.C. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 144 10 (2003) 4241-4249
29. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., and Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 5331 (1997) 1508-1510
30. Liu M.M., Albanese C., Anderson C.M., Hilty K., Webb P., Uht R.M., Price Jr. R.H., Pestell R.G., and Kushner P.J. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J. Biol. Chem. 277 27 (2002) 24353-24360
31. Barkhem T., Carlsson B., Nilsson Y., Enmark E., Gustafsson J., and Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54 1 (1998) 105-112
32. An J., Tzagarakis-Foster C., Scharschmidt T.C., Lomri N., and Leitman D.C. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276 21 (2001) 17808-17814
33. Adesanya O.O., Zhou J., and Bondy C.A. Sex steroid regulation of insulin-like growth factor system gene expression and proliferation in primate myometrium. J. Clin. Endocrinol. Metab. 81 5 (1996) 1967-1974
34. Sahlin L., Norstedt G., and Eriksson H. Estrogen regulation of the estrogen receptor and insulinlike growth factor-I in the rat uterus: a potential coupling between effects of estrogen and IGF-I. Steroids 59 7 (1994) 421-430
35. Moggs J.G., Tinwell H., Spurway T., Chang H.S., Pate I., Lim F.L., Moore D.J., Soames A., Stuckey R., Currie R., Zhu T., Kimber I., Ashby J., and Orphanides G. Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ. Health Perspect. 112 16 (2004) 1589-1606
36. Kretzschmar G., Vollmer G., Schwab P., Tischer S., Metz P., and Zierau O. Effects of the chemically synthesized flavanone 7-(O-prenyl)naringenin-4′-acetate on the estrogen signaling pathway in vivo and in vitro. J. Steroid Biochem. Mol. Biol. 107 1-2 (2007) 114-119
37. Rosenfeld R.G., and Dollar L.A. Characterization of the somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) receptor on cultured human fibroblast monolayers: regulation of receptor concentrations by SM-C/IGF-I and insulin. J. Clin. Endocrinol. Metab. 55 3 (1982) 434-440
38. Rosenfeld R.G., Hintz R.L., and Dollar L.A. Insulin-induced loss of insulin-like growth factor-I receptors on IM-9 lymphocytes. Diabetes 31 5 Pt 1 (1982) 375-381
39. Sundstrom S.A., Komm B.S., Ponce-de-Leon H., Yi Z., Teuscher C., and Lyttle C.R. Estrogen regulation of tissue-specific expression of complement C3. J. Biol. Chem. 264 28 (1989) 16941-16947
40. Zierau O., Geis R.B., Tischer S., Schwab P., Metz P., and Vollmer G. Uterine effects of the phytoestrogen 6-(1,1-dimethylallyl)naringenin in rats. Planta Med. 70 7 (2004) 590-593
41. Vik D.P., Amiguet P., Moffat G.J., Fey M., Amiguet-Barras F., Wetsel R.A., and Tack B.F. Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence. Biochemistry 30 4 (1991) 1080-1085
42. Cenni B., and Picard D. Ligand-independent activation of steroid receptors: new roles for old players. Trends Endocrinol. Metab. 10 2 (1999) 41-46
43. Smith C.L. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 58 3 (1998) 627-632
44. Schmidt S., Degen G.H., Seibel J., Hertrampf T., Vollmer G., and Diel P. Hormonal activity of combinations of genistein, bisphenol A and 17beta-estradiol in the female Wistar rat. Arch. Toxicol. 80 12 (2006) 839-845
45. Malamas M.S., Manas E.S., McDevitt R.E., Gunawan I., Xu Z.B., Collini M.D., Miller C.P., Dinh T., Henderson R.A., Keith Jr. J.C., and Harris H.A. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J. Med. Chem. 47 21 (2004) 5021-5040
46. Frasor J., Barnett D.H., Danes J.M., Hess R., Parlow A.F., and Katzenellenbogen B.S. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology 144 7 (2003) 3159-3166
47. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., and Katzenellenbogen J.A. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J. Med. Chem. 43 26 (2000) 4934-4947
48. Skliris G.P., Munot K., Bell S.M., Carder P.J., Lane S., Horgan K., Lansdown M.R., Parkes A.T., Hanby A.M., Markham A.F., and Speirs V. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J. Pathol. 201 2 (2003) 213-220
49. Horvath L.G., Henshall S.M., Lee C.S., Head D.R., Quinn D.I., Makela S., Delprado W., Golovsky D., Brenner P.C., O'Neill G., Kooner R., Stricker P.D., Grygiel J.J., Gustafsson J.A., and Sutherland R.L. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 61 14 (2001) 5331-5335
50. Leav I., Lau K.M., Adams J.Y., McNeal J.E., Taplin M.E., Wang J., Singh H., and Ho S.M. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159 1 (2001) 79-92
51. Weihua Z., Saji S., Makinen S., Cheng G., Jensen E.V., Warner M., and Gustafsson J.A. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc. Natl. Acad. Sci. U.S.A. 97 11 (2000) 5936-5941
52. Pettersson K., Grandien K., Kuiper G.G., and Gustafsson J.A. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol. Endocrinol. 11 10 (1997) 1486-1496
53. Cowley S.M., Hoare S., Mosselman S., and Parker M.G. Estrogen receptors alpha and beta form heterodimers on DNA. J. Biol. Chem. 272 32 (1997) 19858-19862